Who is to blame for the Alzheimer’s dementia?
Canadian scientists have published the results of the long-term study on the transplantation of autologous blood cells producing stem cells for aggressive multiple sclerosis.
According to this publication 70% of the 24 study participants were free from MS-activity during the next three years, it revealed no relapses, no further brain lesions or no signs of disease progression. None of the surviving participants (one participant died) needed disease-modifying therapy during the next 4 to 13-years follow-up review, 40% of the study participants had even a decrease of the disability.
“These results point to the fact that the degenerative Multiple Sklerose in certain patients may be stopped with an efficient but risky treatment”, noted Vice President of the National MS Society Dr. Bruce Beto, commenting on the results of this study.
The Hematopoetic Stem Cell Therapy (HSCT) is still an experimental method, which tries to “restart” the immune system in order to stop the typical MS-attacks on brain and spinal cord. Due to high risk of infection the Hematopoetic Stem Cell Therapy shall only be applied, if MS advances extremely rapidly and cannot be controlled by the established therapies.
The Lancet, 9. Juni 2016; doi: 10.1016/S0140-6736(16)30169-6